The FDA has just announced a new reminder of this common daily medicine
Officials draw the product due to a serious health risk he poses.
For millions of patients,Daily drugs May be a way to control certain medical conditions. And if you use them to manage your cholesterol andarterial pressure Or to help get a good night's sleep, they can be essential to maintain your overall health. But now Food & Drug Administration has warned that a daily daily drug could present a serious health risk for those who take them. Read the rest for more information on the agency's latest reminder.
Read this then:Walmart has just issued this urgent warning for buyers in more than 100 stores.
Another medication has recently been recalled due to a potential security problem.
No matter what they are used to treat, drugs are designed to keep us safe and healthy. But from time to time, civil servants are forced to draw products that could put people they intend to help in the manner of damage. And in some recent cases, this can even be summed upHow the drug is packed.
For example, on June 29, the FDA announced that Bryant Ranch PREPACK Inc. had published a voluntary reminder of many of hisSulfate morphine 30 mg prolonged release tablets and the prolonged release of the morphine sulfate 60 mg. The company pulled the product after discovering that some packages had been poorly labeled by exchanging the amount of the dose.
The agency warned that such a mixture could lead patients to accidentally take a higher dose of drugs and overdosage or a person taking a lower dose than it was planning and finds himself in weaning or with untreated pain. As such, the FDA advised anyone bearing the medication with the number of lots 179642 and 179643 to stop using it immediately. But now another type of daily medication is being produced for a similar reason.
The FDA has just announced a new reminder on a common daily medicine.
On July 6, the FDA announced that Mylan Pharmaceuticals Inc. had issued a voluntary reminder of a lot ofGlargine insulin injection (glargine-yfgn insulin), 100 units / ml (U-100). The medication is packed in prefabilled 3 ml pens that arise in five -way boxes at consumers. The lot in question was distributed in the United States between April 4, 2022 and May 5, 2022.
Patients can identify the product recalled by the NDC 49502-394-75 number, LOT number BF21002895 and the expiration date August 2023 printed on the box. The agency also specifies that the recall only concerns the pens without brand glargine-yfgn, and not Biosimilaire brand pens of brand interchangeable brand.
RELATED:For more up-to-date information, register for our daily newsletter.
An packaging error may have a serious health risk for patients.
According to the reminder, the company pulled insulin pens after discovering that it could miss a label.AE0FCC31AE342FD3A1346EBB1F342FCB
As the product is long -term insulin increase the products and use bad strength, which potentially leads to "serious complications".
Here is what you need to do if you have the insulin recalled.
Although no unfavorable medical event linked to insulin has yet been reported, the FDA advises any person with the medication assigned to call the SEDGWICK management company at 1-877-643-8438 so that the Company can provide a documentation package to return the product.
Anyone with questions about the recall can also reach the Division of Customers with the Mother Viatris company by calling 1-800-796-9526 on weekdays between 8 a.m. and 5 p.m. Is or send an email to [email protected]. The agency also urges patients who believe they have health problems related to the product recalled to call their doctor or health care provider immediately.
